S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
Log in

NASDAQ:STRO - Sutro Biopharma Stock Price, Forecast & News

$10.06
-0.11 (-1.08 %)
(As of 02/26/2020 04:00 PM ET)
Today's Range
$10.02
Now: $10.06
$11.53
50-Day Range
$9.90
MA: $11.42
$12.16
52-Week Range
$7.69
Now: $10.06
$12.75
Volume42,681 shs
Average Volume71,911 shs
Market Capitalization$232.29 million
P/E RatioN/A
Dividend YieldN/A
Beta1.12
Sutro Biopharma, Inc operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:STRO
CUSIPN/A
CIKN/A
Phone650-392-8412

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$38.42 million
Book Value($6.58) per share

Profitability

Net Income$-35,320,000.00

Miscellaneous

Employees141
Market Cap$232.29 million
Next Earnings Date4/6/2020 (Estimated)
OptionableNot Optionable

Receive STRO News and Ratings via Email

Sign-up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter.


Sutro Biopharma (NASDAQ:STRO) Frequently Asked Questions

What is Sutro Biopharma's stock symbol?

Sutro Biopharma trades on the NASDAQ under the ticker symbol "STRO."

How were Sutro Biopharma's earnings last quarter?

Sutro Biopharma Inc (NASDAQ:STRO) issued its quarterly earnings results on Friday, November, 8th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.09. The company had revenue of $12.28 million for the quarter, compared to analyst estimates of $8.88 million. View Sutro Biopharma's Earnings History.

When is Sutro Biopharma's next earnings date?

Sutro Biopharma is scheduled to release their next quarterly earnings announcement on Monday, April 6th 2020. View Earnings Estimates for Sutro Biopharma.

What price target have analysts set for STRO?

7 brokers have issued 12-month price objectives for Sutro Biopharma's stock. Their forecasts range from $16.00 to $22.00. On average, they expect Sutro Biopharma's share price to reach $19.17 in the next year. This suggests a possible upside of 90.5% from the stock's current price. View Analyst Price Targets for Sutro Biopharma.

What is the consensus analysts' recommendation for Sutro Biopharma?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sutro Biopharma in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sutro Biopharma.

What are Wall Street analysts saying about Sutro Biopharma stock?

Here are some recent quotes from research analysts about Sutro Biopharma stock:
  • 1. According to Zacks Investment Research, "Sutro Biopharma Inc. develops and manufactures pharmaceutical products. The Company provides antibody drug conjugate and multi-specific antibody-based therapeutics for cancer therapy. Its product pipeline consists of STRO-001 and STRO-002 which are in clinical stage. Sutro Biopharma Inc. is based in South San Francisco, California. " (1/14/2020)
  • 2. HC Wainwright analysts commented, "Valuation and risks to our investment thesis. Our 12-month, $18 price target on shares of Sutro is derived from a 13-year DCF-based, sum-of-the-parts analysis. Our DCF is driven by: beta of 1.60, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.3%, and tax rate of 15% beginning in FY 2029. Until clarity on Sutro’s collaboration with Celgene and Merck crystallizes, our $18 price target remains leveraged on the outcome of STRO-002’s safety and efficacy outcome, which represents approximately 67% of our rNPV of $12 per share." (5/7/2019)

Has Sutro Biopharma been receiving favorable news coverage?

News coverage about STRO stock has trended somewhat negative this week, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Sutro Biopharma earned a news impact score of -1.2 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Sutro Biopharma.

Are investors shorting Sutro Biopharma?

Sutro Biopharma saw a decline in short interest during the month of February. As of February 14th, there was short interest totalling 46,200 shares, a decline of 12.2% from the January 30th total of 52,600 shares. Based on an average daily volume of 72,000 shares, the days-to-cover ratio is presently 0.6 days. Currently, 0.5% of the shares of the stock are sold short. View Sutro Biopharma's Current Options Chain.

Who are some of Sutro Biopharma's key competitors?

What other stocks do shareholders of Sutro Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sutro Biopharma investors own include Agile Therapeutics (AGRX), Anavex Life Sciences (AVXL), Momo (MOMO), Sorrento Therapeutics (SRNE), Vaxart (VXRT), AcelRx Pharmaceuticals (ACRX), Aduro BioTech (ADRO), Crispr Therapeutics (CRSP), Fortress Biotech (FBIO) and Krystal Biotech (KRYS).

Who are Sutro Biopharma's key executives?

Sutro Biopharma's management team includes the folowing people:
  • Mr. William J. Newell, CEO & Director (Age 61)
  • Dr. Trevor J. Hallam, Chief Scientific Officer (Age 60)
  • Dr. Arturo M. Molina, Chief Medical Officer (Age 60)
  • Dr. James R. Swartz Sc.D., Ph.D., Founder and Member of Scientific Advisory Board
  • Mr. Edward C. Albini, CFO & Sec. (Age 61)

When did Sutro Biopharma IPO?

(STRO) raised $75 million in an IPO on Thursday, September 27th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are Sutro Biopharma's major shareholders?

Sutro Biopharma's stock is owned by a number of of retail and institutional investors. Top institutional investors include Eventide Asset Management LLC (5.39%), BVF Inc. IL (1.50%), Driehaus Capital Management LLC (1.22%), State Street Corp (0.73%), FMR LLC (0.69%) and Granite Point Capital Management L.P. (0.43%). Company insiders that own Sutro Biopharma stock include Daniel H Petree, Merck & Co, Inc and Trevor Hallam. View Institutional Ownership Trends for Sutro Biopharma.

Which institutional investors are selling Sutro Biopharma stock?

STRO stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Creative Planning and Victory Capital Management Inc.. View Insider Buying and Selling for Sutro Biopharma.

Which institutional investors are buying Sutro Biopharma stock?

STRO stock was acquired by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, Granite Point Capital Management L.P., Victory Capital Management Inc., Jacobs Levy Equity Management Inc., Janus Henderson Group PLC, Spark Investment Management LLC, Acadian Asset Management LLC and Oxford Asset Management LLP. View Insider Buying and Selling for Sutro Biopharma.

How do I buy shares of Sutro Biopharma?

Shares of STRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Sutro Biopharma's stock price today?

One share of STRO stock can currently be purchased for approximately $10.06.

How big of a company is Sutro Biopharma?

Sutro Biopharma has a market capitalization of $232.29 million and generates $38.42 million in revenue each year. The company earns $-35,320,000.00 in net income (profit) each year or ($6.13) on an earnings per share basis. Sutro Biopharma employs 141 workers across the globe.View Additional Information About Sutro Biopharma.

What is Sutro Biopharma's official website?

The official website for Sutro Biopharma is http://www.sutrobio.com/.

How can I contact Sutro Biopharma?

Sutro Biopharma's mailing address is 310 Utah Avenue Suite 150, South San Francisco CA, 94080. The company can be reached via phone at 650-392-8412.


MarketBeat Community Rating for Sutro Biopharma (NASDAQ STRO)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  66 (Vote Outperform)
Underperform Votes:  78 (Vote Underperform)
Total Votes:  144
MarketBeat's community ratings are surveys of what our community members think about Sutro Biopharma and other stocks. Vote "Outperform" if you believe STRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel